{"title":"[Progress in the application of JAK inhibitors in atopic dermatitis].","authors":"W Yao, H Y Wang","doi":"10.3760/cma.j.cn112150-20241016-00820","DOIUrl":null,"url":null,"abstract":"<p><p>Atopic dermatitis is a chronic recurrent inflammatory skin disorder associated with heterogenous presentation and immense patient burden. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants, glucocorticoids and biologcis, etc. In recent years, a variety of small molecule drugs have been approved for the treatment of atopic dermatitis.Two selective JAK inhibitors Upadacitinib and Abrocitinib, have been approved for AD treatment indications in China. This mini-review summarizes the clinical application of these two drugs in the treatment of AD, including the underlying molecular mechanisms, clinical trials, and clinical experiences, highlighting the value of selective JAK inhibitors in AD therapy.</p>","PeriodicalId":24033,"journal":{"name":"中华预防医学杂志","volume":"59 9","pages":"1566-1574"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华预防医学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/cma.j.cn112150-20241016-00820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Atopic dermatitis is a chronic recurrent inflammatory skin disorder associated with heterogenous presentation and immense patient burden. Previous therapeutic drugs include topical glucocorticoids, topical calcineurin inhibitors, oral antihistamines, systemic immunosuppressants, glucocorticoids and biologcis, etc. In recent years, a variety of small molecule drugs have been approved for the treatment of atopic dermatitis.Two selective JAK inhibitors Upadacitinib and Abrocitinib, have been approved for AD treatment indications in China. This mini-review summarizes the clinical application of these two drugs in the treatment of AD, including the underlying molecular mechanisms, clinical trials, and clinical experiences, highlighting the value of selective JAK inhibitors in AD therapy.
期刊介绍：
Chinese Journal of Preventive Medicine (CJPM), the successor to Chinese Health Journal , was initiated on October 1, 1953. In 1960, it was amalgamated with the Chinese Medical Journal and the Journal of Medical History and Health Care , and thereafter, was renamed as People’s Care . On November 25, 1978, the publication was denominated as Chinese Journal of Preventive Medicine . The contents of CJPM deal with a wide range of disciplines and technologies including epidemiology, environmental health, nutrition and food hygiene, occupational health, hygiene for children and adolescents, radiological health, toxicology, biostatistics, social medicine, pathogenic and epidemiological research in malignant tumor, surveillance and immunization.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
